FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100197246> ?p ?o ?g. }

• W3100197246 abstract "Background Checkpoint blockade therapies have transformed the landscape of cancer care. Durable clinical responses have been observed in a subset of patients. However, many patients do not respond, and understanding the mechanisms that determine tumor resistant to checkpoint blockade drugs could potentially benefit more patients. Ferroptosis is a relatively newly described form of regulated cell death distinct from apoptosis and necroptosis. Recently, T cell-promoted tumor ferroptosis was shown to be an anti-tumor mechanism and targeting this pathway could be a potential therapeutic approach. Methods To identify genes critical to immunotherapy resistance, B16.SIY cells were transduced with a genome-scale gRNA lentivirus to generate loss of function mutants. In vitro-primed CD8+ T cells isolated from 2C/Rag2–/– TCR transgenic mice specific for the SIY antigen were co-cultured with transduced B16.SIY tumor cells. Resistant mutants were identified by sequencing the gRNAs of survival clones. The gene encoding Decr2, a peroxisomal 2,4-dienoyl-CoA reductase, was identified. To investigate the role of Decr2 in tumor growth and immune responses in vivo, the Decr2 knock-down or Decr2 overexpressed tumors were transplanted into B6 mice and the mice were subsequently treated with anti-PD-L1 antibody. The tumor microenvironments were analyzed by flow cytometry. To understand the resistance mechanism of Decr2 knock-down tumors, RNA-seq was performed and analyzed. The CD8+ T cell mediated tumor ferroptosis in vitro and in vivo was analyzed for lipid reactive oxygen species. Results Decr2 mutants were relatively resistant to CD8+ T cell killing in vitro. Consistent with this resistance to CD8+ T cell killing, Decr2 knock-down tumors showed minimal response to anti-PDL1 therapy in vivo. RNA-seq analysis of Decr2 knock-down B16.SIY tumors revealed upregulation of ferroptosis-related genes, including slc7a11. Further mechanistic studies showed that Decr2 knock-down tumors displayed defects in ferroptosis in vitro and in vivo. Conclusions Decr2-deficient tumors were relatively resistant to CD8+ T cell killing in vitro and anti-PD-L1 immunotherapy in vivo by modulating CD8+ T cell-induced ferroptosis." @default.
• W3100197246 created "2020-11-23" @default.
• W3100197246 creator A5001201877 @default.
• W3100197246 creator A5044507129 @default.
• W3100197246 creator A5048450334 @default.
• W3100197246 creator A5057828787 @default.
• W3100197246 creator A5085317448 @default.
• W3100197246 date "2020-11-01" @default.
• W3100197246 modified "2023-10-17" @default.
• W3100197246 title "239 Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis" @default.
• W3100197246 cites W2057279877 @default.
• W3100197246 cites W2320640765 @default.
• W3100197246 cites W2728594144 @default.
• W3100197246 cites W2996356523 @default.
• W3100197246 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0239" @default.
• W3100197246 hasPublicationYear "2020" @default.
• W3100197246 type Work @default.
• W3100197246 sameAs 3100197246 @default.
• W3100197246 citedByCount "2" @default.
• W3100197246 countsByYear W31001972462021 @default.
• W3100197246 countsByYear W31001972462022 @default.
• W3100197246 crossrefType "journal-article" @default.
• W3100197246 hasAuthorship W3100197246A5001201877 @default.
• W3100197246 hasAuthorship W3100197246A5044507129 @default.
• W3100197246 hasAuthorship W3100197246A5048450334 @default.
• W3100197246 hasAuthorship W3100197246A5057828787 @default.
• W3100197246 hasAuthorship W3100197246A5085317448 @default.
• W3100197246 hasConcept C154317977 @default.
• W3100197246 hasConcept C167672396 @default.
• W3100197246 hasConcept C190283241 @default.
• W3100197246 hasConcept C202751555 @default.
• W3100197246 hasConcept C203014093 @default.
• W3100197246 hasConcept C2776090121 @default.
• W3100197246 hasConcept C2777701055 @default.
• W3100197246 hasConcept C2780674031 @default.
• W3100197246 hasConcept C31573885 @default.
• W3100197246 hasConcept C502942594 @default.
• W3100197246 hasConcept C55493867 @default.
• W3100197246 hasConcept C86803240 @default.
• W3100197246 hasConcept C8891405 @default.
• W3100197246 hasConcept C94030615 @default.
• W3100197246 hasConceptScore W3100197246C154317977 @default.
• W3100197246 hasConceptScore W3100197246C167672396 @default.
• W3100197246 hasConceptScore W3100197246C190283241 @default.
• W3100197246 hasConceptScore W3100197246C202751555 @default.
• W3100197246 hasConceptScore W3100197246C203014093 @default.
• W3100197246 hasConceptScore W3100197246C2776090121 @default.
• W3100197246 hasConceptScore W3100197246C2777701055 @default.
• W3100197246 hasConceptScore W3100197246C2780674031 @default.
• W3100197246 hasConceptScore W3100197246C31573885 @default.
• W3100197246 hasConceptScore W3100197246C502942594 @default.
• W3100197246 hasConceptScore W3100197246C55493867 @default.
• W3100197246 hasConceptScore W3100197246C86803240 @default.
• W3100197246 hasConceptScore W3100197246C8891405 @default.
• W3100197246 hasConceptScore W3100197246C94030615 @default.
• W3100197246 hasLocation W31001972461 @default.
• W3100197246 hasOpenAccess W3100197246 @default.
• W3100197246 hasPrimaryLocation W31001972461 @default.
• W3100197246 hasRelatedWork W16473764 @default.
• W3100197246 hasRelatedWork W20203410 @default.
• W3100197246 hasRelatedWork W2151330 @default.
• W3100197246 hasRelatedWork W25833474 @default.
• W3100197246 hasRelatedWork W29670928 @default.
• W3100197246 hasRelatedWork W29948911 @default.
• W3100197246 hasRelatedWork W32318761 @default.
• W3100197246 hasRelatedWork W35513613 @default.
• W3100197246 hasRelatedWork W39373733 @default.
• W3100197246 hasRelatedWork W7831382 @default.
• W3100197246 isParatext "false" @default.
• W3100197246 isRetracted "false" @default.
• W3100197246 magId "3100197246" @default.
• W3100197246 workType "article" @default.